646 related articles for article (PubMed ID: 12562577)
41. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
[TBL] [Abstract][Full Text] [Related]
42. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
[TBL] [Abstract][Full Text] [Related]
43. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
[TBL] [Abstract][Full Text] [Related]
44. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
[TBL] [Abstract][Full Text] [Related]
45. Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
Lataster J; van Os J; de Haan L; Thewissen V; Bak M; Lataster T; Lardinois M; Delespaul PA; Myin-Germeys I
J Clin Psychiatry; 2011 Oct; 72(10):1397-404. PubMed ID: 21208588
[TBL] [Abstract][Full Text] [Related]
46. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
[TBL] [Abstract][Full Text] [Related]
47. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
[TBL] [Abstract][Full Text] [Related]
48. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
49. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
Hamilton SH; Revicki DA; Genduso LA; Beasley CM
Neuropsychopharmacology; 1998 Jan; 18(1):41-9. PubMed ID: 9408917
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
51. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
52. D2 receptor occupancy under recommended and high doses of olanzapine.
Harvey EJ; Taylor DM; Flanagan RJ
J Psychopharmacol; 2001 Sep; 15(3):213-4. PubMed ID: 11565632
[No Abstract] [Full Text] [Related]
53. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
54. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
[TBL] [Abstract][Full Text] [Related]
55. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
Wright P; Meehan K; Birkett M; Lindborg SR; Taylor CC; Morris P; Breier A
Clin Ther; 2003 May; 25(5):1420-8. PubMed ID: 12867218
[TBL] [Abstract][Full Text] [Related]
56. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
Ishigooka J; Inada T; Miura S
Psychiatry Clin Neurosci; 2001 Aug; 55(4):403-14. PubMed ID: 11442893
[TBL] [Abstract][Full Text] [Related]
57. Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
Schmitt GJ; Meisenzahl EM; Dresel S; Tatsch K; Rossmüller B; Frodl T; Preuss UW; Hahn K; Möller HJ
J Psychopharmacol; 2002 Sep; 16(3):200-6. PubMed ID: 12236625
[TBL] [Abstract][Full Text] [Related]
58. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
[TBL] [Abstract][Full Text] [Related]
59. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.
Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
J Clin Psychopharmacol; 2013 Oct; 33(5):675-81. PubMed ID: 23948784
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of olanzapine: an overview of pivotal clinical trials.
Beasley CM; Tollefson GD; Tran PV
J Clin Psychiatry; 1997; 58 Suppl 10():7-12. PubMed ID: 9265910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
